FNTB

Across TCGA pan-cancer cohorts, FNTB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FNTB data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FNTB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FNTB expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

GBM, LUAD, and PDAC are the cancer types where FNTB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.406	0.650	<.001	23	view →
LUAD	DFS	Quartile	All	0.954	0.845	.008	22	view →
PDAC	OS	Tertile	III,IV	0.321	0.680	.005	17	view →
CCRCC	DFS	Median	III,IV	0.985	0.067	.008	9	view →
HNSC	OS	Tertile	IV	0.987	0.655	.013	7	view →
UCEC	OS	Median	III,IV	0.554	0.884	.045	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.904	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FNTB–GBM (OS)

Open the GBM breakdown →